Pharmaceutical

Sharps Technology Secures SC Asset Purchase Exclusivity with $1 Million Escrow Deposit

InjectEZ acquisition establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. has progressed with the payment of…

4 months ago

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline…

4 months ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE…

4 months ago

Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts

Appoints David Sutherland, CPA, as Vice President of Finance and ControllerBOSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc.,…

4 months ago

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate…

4 months ago

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, June 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its…

4 months ago

Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress

100% of treated patients in Arm 1 achieved virologic response by Week 28 Most patients also achieved ALT normalization and…

4 months ago

VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week…

4 months ago

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024

Presentation to highlight statistically significant Phase 3 results of Tonmya™ (TNX-102 SL) for the management of fibromyalgia New Drug Application…

4 months ago

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company developing and delivering…

4 months ago